AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Adenylate kinase 7

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96M32

UPID:

KAD7_HUMAN

Alternative names:

ATP-AMP transphosphorylase 7

Alternative UPACC:

Q96M32; Q8IYP6

Background:

Adenylate kinase 7, also known as ATP-AMP transphosphorylase 7, plays a crucial role in cellular energy homeostasis by catalyzing the transfer of phosphate groups between nucleoside triphosphates and monophosphates. It exhibits the highest activity towards AMP and is involved in maintaining ciliary structure and function, highlighting its importance in cellular mechanics and signaling.

Therapeutic significance:

The protein's association with Spermatogenic failure 27, a disorder characterized by defects in spermatogenesis leading to abnormal sperm flagella, underscores its potential as a target for therapeutic intervention. Understanding the role of Adenylate kinase 7 could open doors to potential therapeutic strategies for treating infertility issues related to spermatogenic defects.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.